NO320194B1 - Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning - Google Patents

Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO320194B1
NO320194B1 NO19991590A NO991590A NO320194B1 NO 320194 B1 NO320194 B1 NO 320194B1 NO 19991590 A NO19991590 A NO 19991590A NO 991590 A NO991590 A NO 991590A NO 320194 B1 NO320194 B1 NO 320194B1
Authority
NO
Norway
Prior art keywords
tetrahydro
oxo
benzazepine
propyloxy
acetic acid
Prior art date
Application number
NO19991590A
Other languages
English (en)
Norwegian (no)
Other versions
NO991590D0 (no
NO991590L (no
Inventor
James Francis Callahan
Richard Mccullock Keenan
Russell Donovan Cousins
Irene Nijole Uzinskas
Chet Kwon
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO991590D0 publication Critical patent/NO991590D0/no
Publication of NO991590L publication Critical patent/NO991590L/no
Publication of NO320194B1 publication Critical patent/NO320194B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19991590A 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning NO320194B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (3)

Publication Number Publication Date
NO991590D0 NO991590D0 (no) 1999-03-31
NO991590L NO991590L (no) 1999-05-31
NO320194B1 true NO320194B1 (no) 2005-11-14

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991590A NO320194B1 (no) 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning

Country Status (37)

Country Link
EP (1) EP0957917B1 (de)
JP (2) JP4491072B2 (de)
KR (1) KR100589578B1 (de)
CN (1) CN1114403C (de)
AP (1) AP1463A (de)
AR (1) AR008878A1 (de)
AT (1) ATE312089T1 (de)
AU (1) AU733417B2 (de)
BG (1) BG64581B1 (de)
BR (1) BR9712248B1 (de)
CA (1) CA2267224C (de)
CO (1) CO4900046A1 (de)
CY (1) CY2576B1 (de)
CZ (1) CZ299076B6 (de)
DE (1) DE69734833T2 (de)
DK (1) DK0957917T3 (de)
DZ (1) DZ2320A1 (de)
EA (1) EA002419B1 (de)
ES (1) ES2252775T3 (de)
HK (1) HK1023730A1 (de)
HU (1) HU229221B1 (de)
ID (1) ID19623A (de)
IL (1) IL129243A (de)
MA (1) MA24361A1 (de)
MY (1) MY137606A (de)
NO (1) NO320194B1 (de)
NZ (1) NZ334953A (de)
PE (1) PE10499A1 (de)
PL (1) PL190859B1 (de)
RO (1) RO119881B1 (de)
SA (1) SA98180936B1 (de)
SK (1) SK285029B6 (de)
TR (1) TR199900737T2 (de)
TW (1) TW487702B (de)
UA (1) UA60311C2 (de)
UY (2) UY24735A1 (de)
WO (1) WO1998014192A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JP2002528380A (ja) * 1997-09-24 2002-09-03 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
EP1023073A1 (de) * 1997-09-24 2000-08-02 Smithkline Beecham Corporation Vitronectin-rezeptor-antagonist
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
AU747503B2 (en) * 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
ATE258439T1 (de) * 1999-04-30 2004-02-15 Univ Michigan Verwendung von benzodiazepinen zur behandlung von apoptose-induzierten autoimmunerkrankungen
EP1208101A4 (de) * 1999-08-06 2003-03-19 Smithkline Beecham Corp Zur behandlung von schlaganfällen nützliche vitronektin-rezeptor-antagonisten
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
CA2443734A1 (en) * 2001-04-10 2002-10-24 Smithkline Beecham Corporation Method of inhibiting adhesion formation
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008524334A (ja) * 2004-12-21 2008-07-10 スミスクライン・ビーチャム・コーポレイション 方法および処方
CA2631173A1 (en) * 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment method
JP5637855B2 (ja) 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
ES2428896T3 (es) * 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
US20120095215A1 (en) 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (de) * 2009-11-24 2011-05-25 Glycotope GmbH Verfahren zur Reinigung von Glykoproteinen
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2021218863A1 (zh) * 2020-04-26 2021-11-04 江苏恩华药业股份有限公司 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332860T2 (de) * 1992-12-21 2004-03-11 Smithkline Beecham Corp. Bicyklische fibrinogen antagoniste
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
JPH10504808A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
EP0777657A1 (de) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclische verbindungen
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
AP9901493A0 (en) 1999-03-31
EA199900356A1 (ru) 2000-02-28
DE69734833D1 (de) 2006-01-12
AU733417B2 (en) 2001-05-17
IL129243A0 (en) 2000-02-17
HU229221B1 (en) 2013-09-30
JP4491072B2 (ja) 2010-06-30
HUP9903769A2 (hu) 2000-03-28
HK1023730A1 (en) 2000-09-22
CN1238689A (zh) 1999-12-15
ES2252775T3 (es) 2006-05-16
PL190859B1 (pl) 2006-02-28
AU4746297A (en) 1998-04-24
BG103299A (en) 2000-01-31
UY24735A1 (es) 1998-03-30
UY24935A1 (es) 2001-07-31
ATE312089T1 (de) 2005-12-15
TR199900737T2 (xx) 1999-07-21
TW487702B (en) 2002-05-21
AR008878A1 (es) 2000-02-23
CA2267224A1 (en) 1998-04-09
AP1463A (en) 2005-09-10
SA98180936B1 (ar) 2006-05-30
SK42599A3 (en) 1999-12-10
IL129243A (en) 2004-07-25
WO1998014192A1 (en) 1998-04-09
CY2576B1 (en) 2008-07-02
HUP9903769A3 (en) 2000-07-28
RO119881B1 (ro) 2005-05-30
MA24361A1 (fr) 1998-07-01
EP0957917A1 (de) 1999-11-24
NO991590D0 (no) 1999-03-31
BG64581B1 (bg) 2005-08-31
DK0957917T3 (da) 2006-04-18
EA002419B1 (ru) 2002-04-25
KR100589578B1 (ko) 2006-06-15
CZ299076B6 (cs) 2008-04-16
CA2267224C (en) 2007-03-13
CO4900046A1 (es) 2000-03-27
CN1114403C (zh) 2003-07-16
EP0957917A4 (de) 2002-05-15
DZ2320A1 (fr) 2002-12-28
SK285029B6 (sk) 2006-04-06
NO991590L (no) 1999-05-31
JP2001501936A (ja) 2001-02-13
DE69734833T2 (de) 2006-07-13
CZ113299A3 (cs) 2000-03-15
UA60311C2 (uk) 2003-10-15
KR20000048816A (ko) 2000-07-25
ID19623A (id) 1998-07-23
MY137606A (en) 2009-02-27
NZ334953A (en) 2000-01-28
BR9712248A (pt) 1999-08-24
PE10499A1 (es) 1999-03-27
JP2010006838A (ja) 2010-01-14
BR9712248B1 (pt) 2010-06-29
EP0957917B1 (de) 2005-12-07
PL332674A1 (en) 1999-09-27

Similar Documents

Publication Publication Date Title
NO320194B1 (no) Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning
US6239138B1 (en) Vitronectin receptor antagonist
CA2303846A1 (en) Vitronectin receptor antagonist
SK13292000A3 (sk) Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
CA2304000A1 (en) Vitronectin receptor antagonist
US6825188B2 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US20020123487A1 (en) Vitronectin receptor antagonist
US20020128257A1 (en) Vitronectin receptor antagonist
MXPA00002896A (en) Vitronectin receptor antagonist
MXPA01001386A (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees